Second phase of advantage af study of farapulse™ pulsed field ablation system meets primary safety and efficacy endpoints

Trial achieves positive results in the treatment of persistent atrial fibrillation marlborough, mass. and san diego , april 24, 2025 /prnewswire/ -- boston scientific corporation (nyse: bsx) today announced positive 12-month primary endpoint results from the second phase of the advantage af clinical trial evaluating the use of the farapulse™ pulsed field ablation (pfa) system* and adjunctive use of the farapoint™ pfa catheter in patients with persistent atrial fibrillation (af).
BSX Ratings Summary
BSX Quant Ranking